Insights On Outsourced Drug Development

1. How To Reduce Batch Loss In Biopharma Production 12/12/2025

   Batch failures in biopharma remain costly despite improvements. Learn the leading causes in downstream purification and how supplier expertise can help reduce risk and protect production.

2. Transformative Innovation: Advancing Drug Development Using In Silico Modeling 3/4/2026

   Explore how predictive modeling and in silico strategies can turn complex data into actionable insights that accelerate drug development and reduce risk across the development lifecycle.

3. Benchmarking Filtration Performance Of TFF Cassettes 5/30/2025

   Optimize your protein purification workflow with tangential flow filtration by comparing membrane performance and exploring how protein concentration impacts flux and MWCO selection in lab-scale systems.

4. A Novel Patient-Derived Colorectal Cancer Organoid Platform 4/22/2025

   Patient-derived organoids are revolutionizing drug discovery by mimicking tumors and predicting therapeutic efficacy. Discover a scalable bioprocess that enhances reproducibility and cost-effectiveness to pave the way for broader adoption.

5. Accelerating mRNA Therapy Production With Digital Innovation 10/21/2025

   Scaling mRNA therapies requires more than innovation—it demands precision. Discover how digital tools like automation and analytics are helping life science companies streamline production.

6. What Will It Take To Make MCED And MRD A Reality? 6/30/2026

   Cancer mortality is declining, but the need for earlier action remains. Gain insight into how MCED and MRD are advancing cancer detection and surveillance, helping clinicians identify disease sooner.

7. Scientific Data Is Not AI‑Ready By Default 6/26/2026

   Convert siloed laboratory data into trusted, AI-ready assets. Learn to enforce data integrity principles at the point of origin to streamline analytics and reduce GxP compliance risks.

8. Overcoming Challenges To High-Concentration Formulation Development 3/25/2025

   Explore how the S-HiCon™ platform optimizes high-concentration therapeutic antibody formulations, overcoming stability and manufacturability challenges to deliver safe, effective therapies.

9. Choosing The Best Amorphous Dispersion Path Before It Costs You 6/22/2026

   Parallel screening across multiple solid dispersion platforms early optimizes drug solubility and stability, building a strong technical foundation that prevents costly development delays.

10. Assessing Developability And Designing Advanceable Formulations From The Start 1/15/2026

    Discover how early developability assessments and a quality-by-design approach can streamline formulation, reduce risk, and accelerate your path to successful, cost-effective drug development.